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A B S T R A C T
Introduction. Women with breast cancer have better cancer-related outcomes with the use of aromatase inhibitors
(AIs), but the physiological suppression of estradiol can negatively affect sexual functioning because of unpleasant
urogenital and vaginal symptoms. Local health care practitioners have observed that the beneﬁts of vaginal testos-
terone in allaying these unpleasant symptoms in women with breast cancer are similar to the beneﬁts of vaginal
estrogen in women without breast cancer.
Aim. The aim of this study was to evaluate the effects of using a daily vaginal testosterone cream on the reported
sexual health quality of life in women with breast cancer taking AI therapy.
Methods. Thirteen postmenopausal women with breast cancer on AI therapy and experiencing symptoms of sexual
dysfunction were recruited from an oncology practice. The women were prescribed a 300 μg testosterone vaginal
cream daily for 4 weeks. During the ﬁrst study visit, a vaginal swab was obtained to rule out the presence of Candida
species or Gardnerella vaginalis in participants. Women with positive vaginal swabs were treated prior to starting the
vaginal testosterone therapy.
Main Outcome Measure. The Female Sexual Function Index (FSFI) survey, measuring female sexual health quality
of life, was administered during the ﬁrst study visit and at the ﬁnal study visit, after completing testosterone therapy.
Results. Twelve patients completed 4 weeks of daily vaginal testosterone therapy. When compared with baseline
FSFI scores, there was a statistically signiﬁcant improvement for individual domain scores of desire (P = 0.000),
arousal (P = 0.002), lubrication (P = 0.018), orgasm (P = 0.005), satisfaction (P = 0.001), and pain (P = 0.000). Total
domain scores reﬂecting sexual health quality of life also improved when compared with baseline (P = 0.000).
Conclusions. The use of a compounded testosterone vaginal cream applied daily for 4 weeks improves reported
sexual health quality of life in women with breast cancer taking AIs. Dahir M and Travers-Gustafson D.
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Introduction
Breast cancer is the most common type ofmalignancy among women in the United
States [1]. The advanced technology of mammog-
raphy screening offers early detection anddiagnosis
of breast cancer. In theUnited States, about 75%of
breast cancers are diagnosed in postmenopausal
women, and 80% of them are estrogen receptor
(ER) positive [2]. The recommended treatment for
postmenopausal women with hormone receptor-
positive cancers is estrogen deprivation through the
use of adjuvant endocrine therapy, such as an
aromatase inhibitor (AI). AIs inhibit the synthesis
of estrogen by preventing the aromatase enzyme
from converting androgens to estrogens [3]. Third-
generation AIs suppress up to 98% of circulat-
ing hormones and are considered to be ﬁrst-line
treatment [4].
Women with breast cancer have better cancer-
related outcomes with the use of AIs, but side
effects from the medication can negatively affect
sexual functioning because of the physiologic sup-
pression of estradiol [4–6]. As a result, women
taking AIs aremore likely to experience a decreased
sexual quality of life because of unpleasant urogeni-
tal and vaginal symptoms [7–9]. In 2008, Antoine
et al. surveyed women with breast cancer for
reported quality of life concerns during AI treat-
ment. When compared with non-AI users, women
taking AIs had signiﬁcantly higher rates of vaginal
dryness (P = 0.01), decreased sexual desire (P <
0.02), dissatisfaction with their sexual life (P <
0.01), and sexual dysfunction (P < 0.001) [7].
Baumgart et al. [8] reported in a population-
based study that nearly 600,000 women in the
United States currently take AIs and that these
women are two times more likely than non-treated
women to report symptoms of vulvovaginal
atrophy and painful intercourse. Baumgart and
colleagues evaluated subjective symptoms related
to endocrine changes, such as estrogen deﬁciency,
using the endocrine subscale of the Functional
Assessment of Cancer Therapy-Breast tool. Fifty-
eight percent of participants reported moderate to
severe symptoms of vaginal atrophy, 42% reported
vaginal dryness, and 62% reported pain or discom-
fort during intercourse [8].
The concurrent use of AIs with vaginal estrogen
is generally not recommended because local estro-
gen may interfere with the drug’s ability to sup-
press endogenous estrogen production [3]. The
lack of treatment options is concerning because
the number of women diagnosed with breast
cancer continues to increase; their longevity also
continues to increase with the use of newer adju-
vant chemotherapies [4,10]. The principal investi-
gator (PI) has observed that the beneﬁts of vaginal
testosterone for sexual health in women with
breast cancer are similar to the beneﬁts of vaginal
estrogen in women without breast cancer. Testos-
terone is a U.S. Food and Drug Administration
(U.S. FDA)-approved drug, but currently, the U.S.
FDA has not approved a vaginal testosterone
medication for the treatment of vulvovaginal
symptoms and negative sexual side effects related
to AI use [11]. Testosterone is available off-label,
by prescription, to women through compounding
pharmacies that are licensed and regulated at the
state level [12]. Pharmaceutical compounding
requires sterile technique and a detailed process to
ensure the right drug, weight, and dose; even dis-
tribution of the chemical throughout the base; and
proper distribution of the compounded medica-
tion through the base, such as a cream.
Aim
This study aims to evaluate the effects of using a
300 μg testosterone vaginal cream daily for 4
weeks on the reported sexual health quality of life
in women with breast cancer who take AI therapy.
The authors hypothesized that vaginal testoster-
one therapy would improve sexual functioning in
relation to desire, arousal, lubrication, orgasm, sat-
isfaction, and pain.
Methods
The pilot study was approved by the Creighton
University Institutional Review Board and regis-
tered with Clinicaltrials.gov. Participants were
prospectively recruited from Nebraska Cancer
Specialists in Omaha, Nebraska between January
11, 2013 and April 23, 2013. The target population
was women with breast cancer who take AI therapy
such as anastrozole, letrozole, or exemestane. Eli-
gible participants included women who (i) were
diagnosed with breast cancer and currently on AI
therapy; (ii) had reported urogenital/vulvovaginal
symptoms, such as vaginal dryness and pain with
intercourse; (iii) had reported changes in sexual
health quality of life/sexual functioning since start-
ing AI therapy; (iv) were older than age 50 years;
and (v) were postmenopausal (2 years since last
menstrual cycle). The exclusion criteria included (i)
the use of other treatments for breast cancer, such
as chemotherapy or radiation, within the past 12
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months; (ii) a known sensitivity tomedications con-
taining testosterone; and (iii) the use of exogenous
hormone replacement therapy in the past 3
months, including systemic and local estrogen or
testosterone therapy.
Study Setting and Procedures
Midwest Cancer Center Legacy in Omaha,
Nebraska was the setting for conduct of the study,
meetings with participants, and data collection.
The PI procured initial and ongoing study consent
and served as the sole educator throughout the
study. Participants gave written informed consent
prior to enrolling in the study.
During the ﬁrst study visit, the PI conducted
interviews and performed a physical examination.
The PI procured a vaginal swab (Afﬁrm, Becton
Dickinson & Company, Franklin Lakes, NJ, USA)
prior to prescribing testosterone therapy because
women with suppressed estrogen levels have an
increased risk of infection. A decrease in vaginal
secretions reduces lactic acid production by
lactobacilli, increases the vaginal pH, and predis-
poses the vulvovaginal area to infection [13–15]. In
the clinical setting, the PI has observed that
women who develop a yeast (Candida species) or
bacterial (Gardnerella vaginalis) infection while
using vaginal testosterone frequently report symp-
toms of vaginal itching, burning, or irritation.
Participants with a negative vaginal swab were
prescribed a vaginal testosterone cream, and those
with positive results were treated prior to starting
the intervention. Participants who were treated for
a vaginal infection did not have a repeat vaginal
swab because a test of cure is not standard of
care when the symptoms have resolved [16,17].
The vaginal testosterone cream was prepared by
Precision, a licensed compounding pharmacy in
Omaha, Nebraska, and given to the participants at
no cost. The study drug was supplied in preﬁlled
syringes, and each 0.5 mL dose delivered 300 μg of
testosterone daily. The PI demonstrated proper
application of the vaginal testosterone cream, and
participants were instructed to apply 0.5 mL to
the vaginal opening and clitoris once daily for 4
weeks (28 days). A treatment application protocol
was followed to ensure consistency among partici-
pants in the application of the vaginal testosterone
cream. A mirror was used to demonstrate applica-
tion of the topical testosterone vaginal cream.
After the physical examination, the patient was
reinstructed on how to apply the vaginal testoster-
one cream using a diagram of the vulva.
Main Outcome Measure
The primary end point of the study was to evaluate
the impact of using vaginal testosterone cream on
sexual health quality of life. Participants completed
the Female Sexual Function Index (FSFI) question-
naire prior to starting testosterone therapy (pretest)
and repeated the questionnaire after using the tes-
tosterone cream for 4 weeks (posttest). The FSFI
is a 19-item multidimensional self-administered
questionnaire and takes about 15 minutes to com-
plete. The questionnaire assesses six dimensions
of sexual functioning over the previous 4 weeks.
The dimensions are related to desire, arousal, lubri-
cation, orgasm, satisfaction, and pain; a total FSFI
score less than 26.5 is suggestive of female sexual
dysfunction.
The FSFI questionnaire was constructed by a
group of experts in female sexual functioning to
ensure face validity and that the questions were
not biased, and to determine the ease of adminis-
tration and scoring [18]. The questionnaire was
revised, administered to a larger sample, and re-
administered after 2–4 weeks to establish test–
retest reliability. Reliability has been supported in
numerous studies [19–21].The original researchers
granted permission to use the FSFI questionnaire
free of charge and requested that publications using
the FSFI questionnaire be emailed to them.
Statistics
The quasi-experimental pilot study involved a one-
group pre–posttest design using the FSFI question-
naire and participants serving as their own controls.
The data were collected, recorded, and analyzed
using SPSS 21.0 for Macintosh (SPSS, Inc.,
Chicago, IL, USA). The demographics and char-
acteristics of participants were analyzed by descrip-
tive statistics. The FSFI scores were analyzed by
paired t-test and presented asmean, standard devia-
tion, t-score, and probability (P) values.TheP value
was considered statistically signiﬁcant if P < 0.05. A
power calculation was not used because the inten-
tion for this pilot study was to collect preliminary
data and expand for future research.
Results
There were no participant reports of serious
adverse events to vaginal testosterone therapy. Of
the 13 women enrolled in the study, one withdrew
because of recurrent G. vaginalis. Per study proto-
col, her bacterial vaginal infection was treated
prior to starting testosterone therapy, and the par-
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ticipant used the study drug for 2 weeks. After 2
weeks, the participant reported symptoms of a
recurrent vaginal infection and burning discom-
fort with application of the testosterone cream.
Table 1 shows the participant demographics.
The participants were between the ages of 50 and
69. Themean age of participants was 59.67 years of
age, and all of the participants were married. Most
of the participants were overweight (41.7%) or
obese (41.7%) by body mass index criteria, and all
participants were high school graduates. The mean
time frame from diagnosis of breast cancer to
enrollment in the study was 4.6 years, and the time
frame ranged from 2.2 years to 18.6 years. Prior to
enrolling in the study, 58.3% of participants had
engaged in sexual intercourse within the past 4
weeks. After completing 4 weeks of vaginal testos-
terone therapy, 91.7% of participants had engaged
in sexual intercourse. Two of the participants
shared their thoughts about participating in the
study. One participant stated, “I did not tell my
husband about the study because I did not want to
get his hopes up. He has been patient and I feel bad
for him. I hope you can help me.” Another partici-
pant stated, “My husband doesn’t know I am here
today. I want to surprise him on Valentine’s Day.”
Table 2 shows additional characteristics of the
participants. One-third of the participants were
surgically postmenopausal (surgical removal of
ovaries). Regarding breast tumor characteristics,
91.7% of participants were ER positive, 83.3%
were progesterone receptor positive, and one par-
ticipant (8.3%)was human epidermal growth factor
receptor 2 positive. Anastrozole was the most com-
monly prescribed AI therapy (91.7%), 8.3% were
taking letrozole, and none of the participants was
taking exemestane. Twenty-ﬁve percent of the par-
ticipants were positive for G. vaginalis at the initial
screening, treated successfully prior to study inter-
vention, and none of them was positive for Candida
species. Upon completion of the study, 91.7% of
the participants decided to continue use of vaginal
testosterone therapy, and several participants
offered qualitative feedback (see Table 3).
All FSFI domain scores increased after using
the testosterone vaginal cream, and the ﬁndings
were statistically signiﬁcant. The individual mean
pretreatment to posttreatment domain scores were
as follows: desire: 1.35 to 2.65, P = 0.000; arousal:
1.2 to 2.83, P = 0.002; lubrication: 1.18 to 2.68,
P = 0.018; P = 0.005 for orgasm; P = 0.001 for sat-
isfaction; and P = 0.000 for pain (see Table 3).
The total FSFI posttest scores improved for all
participants when compared with baseline FSFI
scores. Two of the participants had a total posttest
Table 1 Demographics of project participants
N = 12
Percentage
(%) Mean
Age (years) 59.67
Body mass index
18.5–24.9 (normal) 2 16.7
25–29.9 (overweight) 5 41.7
30.0 and above (obese) 5 41.7
Marital status
Married 12 100
Not married 0 0
Sexually active prior to study*
Yes 7 58.3
No 5 41.7
Sexually active during study*
Yes 11 91.7
No 1 8.3
Time from breast cancer
diagnosis to enrollment
in study
Years 4.6
Education
High school degree 3 25
Associate’s degree 3 25
Bachelor’s degree 4 33.3
Master’s degree 2 16.7
*Participants who engaged in sexual intercourse within the past four weeks.
Table 2 Participant characteristics
N = 12
Percentage
(%)
Oophorectomy
Yes 4 33.3
No 8 66.7
Estrogen receptor (ER) status
ER+ 11 91.7
ER− 1 8.3
Progesterone receptor (PR) status
PR+ 10 83.3
PR− 2 16.7
Human epidermal growth factor
receptor 2 (HER2) status
HER2+ 1 8.3
HER2− 11 91.7
Aromatase inhibitor
Anastrozole (Arimidex, Astra
Zeneca, Wilmington, DE, USA)
11 91.7
Letrozole (Femara, Novartis
Pharma, New York, NY, USA)
1 8.3
Exemestane (Aromasin, Pfizer,
New York, NY, USA)
0 0
Vaginal swab test
No vaginal infection 9 75
Gardnerella vaginalis 3 25
Candida species 0 0
Continued vaginal testosterone upon
completion of study
Yes 11 91.7
No 1 8.3
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score greater than 26.5 (a total FSFI score less
than 26.5 is suggestive of sexual dysfunction) (see
Figure 1). The total mean FSFI scores improved
from pretreatment to posttreatment (8.69 to 18.78,
P = 0.000). Although this ﬁnding was statistically
signiﬁcant, the mean posttreatment score was less
than 26.5 and suggests continued female sexual
dysfunction (see Table 4).
Discussion
Testosterone is an important hormone for female
sexual functioning because it facilitates sexual
Table 4 Female Sexual Function Index (FSFI) questionnaire results
Mean score
pretreatment (SD)
Mean score
posttreatment (SD)
t score P value*N = 12 N = 12
FSFI Domains
Sexual desire (score range 1.2–6) 1.35 (0.37) 2.65 (0.87) −5.117 <0.001
Arousal (score range 0–6) 1.2 (0.68) 2.83 (1.26) −4.113 0.002
Lubrication (score range 0–6) 1.18 (0.62) 2.68 (1.93) −2.770 0.018
Orgasm (score range 0–6) 1.73 (1.77) 2.93 (2.05) −3.518 0.005
Satisfaction (score range 0.8–6) 2.3 (1.31) 4.2 (1.29) −4.857 0.001
Pain (score range 0–6) 0.93 (0.88) 3.5 (2.28) −4.960 <0.001
Total FSFI score† (score range 2–36) 8.69 (3.80) 18.78 (7.05) −5.790 <0.001
*Derived from paired t-test
†A total FSFI score less than 26.5 suggests female sexual dysfunction
FSFI = Female Sexual Function Index; SD = standard deviation
Table 3 Qualitative feedback from participants
• I never knew I had options. I hope you can help more women like me.
• After using the cream I was almost pain free—thank you for that.
• I no longer use Vagisil and I feel like my vaginal tissues have healed.
• I have noticed an increase in desire, but I still have pain.
• I feel like things opened up after using the testosterone cream.
• The testosterone cream caused moisture in my vagina within 24 hours of use. Prior to using the cream, there was no moisture.
• I thought there was no hope for me. Now I have moisture in my vagina and hardly any pain.
• I was really happy I did this. I always enjoyed cuddling with my husband, but I feel like I am more alert and aware about sexual thoughts.
I have noticed increased clitoral sensitivity. I still have tenderness around my vaginal opening, but I am hoping it will get better.
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Figure 1 Total FSFI scores for
individual participants.
*A total FSFI score less than 26.5
suggests female sexual dysfunction.
**Participants with a total FSFI score
greater than 26.5.
FSFI = Female Sexual Function
Index.
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response through increased blood ﬂow, vaginal and
clitoral engorgement, sensation, and lubrication
[22,23]. Testosterone therapy has been prescribed
off-label for women since the early 1900s. At the
turn of the last century, little safety data existed on
the use of testosterone in women, and health care
providers prescribed testosterone based on profes-
sional observations in the clinical setting [24].
There is limited research regarding the safety
and efﬁcacy of using local vaginal hormones to
alleviate symptoms associated with AI treatment.
Available evidence suggests that the use of topical
vaginal testosterone may be an appropriate alter-
native to vaginal estrogen treatment in women
with breast cancer who take AIs [25,26]. At the
American Society of Clinical Oncology Breast
Cancer Symposium, Glaser [25] reported ﬁndings
from a proof-of-concept study using testosterone/
anastrozole subcutaneous implants in women
with breast cancer. The study included 43 women
with breast cancer, 40 of whom had ER-positive
cancers. Serum estradiol and testosterone levels
were drawn 2 weeks after each insertion, and about
93% of serum estradiol levels were less than or
equal to 30 pg/mL (the normal range of serum
estradiol levels is less than 41 pg/mL in postmeno-
pausal women) [27]. All women reported relief
of vulvovaginal symptoms related to hormone
deﬁciency, there was no recurrence or progression
of breast cancer over 3 years, and no associated
adverse events were reported. The researcher con-
cluded that subcutaneous implants of anastrozole/
testosterone provide therapeutic levels of testost-
erone and do not cause elevated estradiol levels
[25].
Witherby et al. [26] also recognized the need
for an alternative to vaginal estrogen to treat
vaginal atrophy in women with breast cancer who
take AIs. Uncertainty about whether the use of
vaginal estrogen with AIs decreases the efﬁcacy of
breast cancer treatment led to this phase I/II pilot
study. Two groups of patients (N = 20) received
different daily dosages of testosterone in a com-
pounded vaginal cream. Ten study participants
received a daily 300 μg dose of testosterone, and
10 participants used a 150 μg dose of testosterone
daily. The researchers concluded, per participant
report, that a 4-week course of vaginal testoster-
one improved symptoms of vaginal atrophy
without increasing estradiol or testosterone levels
[26].
Health care providers, regardless of their spe-
cialty, should proactively assess sexual health in
women with breast cancer who are taking AIs
because theymay experience a decrease in quality of
life and sexual functioning because of side effects
from adjuvant endocrine therapy, typically AIs
[7–9]. However, AIs are currently the ﬁrst-line
treatment for hormone receptor-positive tumors in
postmenopausal women because of better cancer-
related outcomes [4,28]. Research regarding the
use of testosterone replacement in women with
breast cancer who take AIs is limited, and the ﬁnd-
ings from this pilot study suggest the use of 300 μg
testosterone vaginal cream daily for 4 weeks
reduces unpleasant urogenital and vaginal symp-
toms and improves related sexual health quality of
life in women with breast cancer on AI therapy.
However, these results should be viewed with
caution because the small sample size may not
accurately reﬂect statistical signiﬁcance. Next, the
pilot study revealed an unexpected secondary
outcome regarding the discovery of G. vaginalis in
several participants during the baseline assessment.
The clinical assessment ﬁndings align with prior
research suggesting thatwomenwith compromised
ovarian functioning have an increased risk for
developing a vaginal infection; as such, the presence
of any vaginal infection must be ruled out prior to
starting testosterone therapy [13–15]. Finally,
vaginal testosterone may be a safe and efﬁcacious
alternative to estrogen inwomen suffering from the
negative sexual side effects related to the use of AIs
[25,26].
Limitations of this pilot study included the
narrow time frame for enrollment and follow-up,
the exclusion of surgically menopausal women
under the age of 50, and the presence of recurrent
G. vaginalis. The small sample size was another
limitation; however, the purpose of conducting a
pilot study is to critique the study procedure, iden-
tify problems with data collection, and improve the
design for an expanded study [29]. Some patients
declined participation in the study because of the
traveling distance for study visits. Other patients
declined participation because they identiﬁed situ-
ational factors that would likely inhibit sexual activ-
ity during the 4-week study. The situational factors
included caring for a daughter with poor health, no
sexual activity due to a long-distance relationship,
and a second surgery for breast reconstruction had
been scheduled during the enrollment time frame.
The following potential threats to validity were
identiﬁed: participants may not represent women
with breast cancer who take AIs in the general
population; sexual functioning may have been
affected by history or events such as relationship
conﬂict, stress, or vacation; and non-adherence
Vaginal Testosterone and Breast Cancer 13
Sex Med 2014;2:8–15© 2014 The Authors. Sexual Medicine published by Wiley Periodicals, Inc.
on behalf of International Society for Sexual Medicine.
with using the vaginal testosterone cream as dem-
onstrated and prescribed.
Conclusions
Sexual health is a state of physical, emotional,
mental, and social well-being [30]. The domains of
sexual functioning (desire, arousal, lubrication,
orgasm, satisfaction, and pain) often do not occur
as a single diagnosis [18]. Rather, each domain
seems to have a “domino effect” in which multiple
problems with sexual functioning can coexist [31].
It is not professional, compassionate, or ethical for
health care providers to ignore or dismiss sexual
functioning, and doing so omits total disease man-
agement [31,32]. In closing, women with breast
cancer who experience symptoms of sexual dys-
function due to AI therapy need to know about
evidence-based treatment options and possible
unknown risks. Results from the current pilot study
suggest that daily topical testosterone treatment
may be an effective therapy to support sexual health
quality of life for womenwith breast cancer who are
on AI therapy. Future prospective studies with
larger sample sizes and more age-inclusive criteria
are needed to establish the safety and efﬁcacy of
testosterone use in women with breast cancer who
take AIs and how it relates to sexual dysfunction.
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